M&A Deal Summary |
|
|---|---|
| Date | 2024-03-18 |
| Target | Adaptive Phage Therapeutics |
| Sector | Life Science |
| Buyer(s) | BiomX |
| Sellers(s) | Deerfield Management |
| Deal Type | Add-on Acquisition |
SEARCH BY
BiomX is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. BiomX was incorporated in 2015 and is based in Ness Ziona, Israel.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-12-19 |
RondinX
Tel Aviv, Israel RondinX Ltd. is a drug discovery platform that develops solutions in the microbiome therapeutic and companion diagnostic spaces. RondinX Ltd. was established in 2015 and is based in Tel Aviv, Israel. |
Buy | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1994 |
| PE ASSETS | 15.0B USD |
| Size | Mega |
| Type | Sector Focused |
Deerfield Management is a hedge fund sponsor focused on public and private company investments in the healthcare sector. Deerfield was established in 1994 and is headquartered in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-03-01 |
Parabilis Medicines
Cambridge, Massachusetts, United States Parabilis Medicines is a biopharmaceutical company with a mission to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that squelch abnormal physiological processes in ways previously imagined but considered unattainable. The company is pioneering the discovery, development and commercialization of Helicon peptides, a new drug modality that uniquely combines the cell-permeability and oral dosing optionality of traditional small molecule drugs with the high specificity, broad target accessibility and rapid discovery arc of monoclonal antibody drugs. Parabilis Medicines was founded in 2016 and is based in Cambridge, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-12-23 |
Singular Genomics
San Diego, California, United States Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. Its G4 Sequencing Platform is a versatile benchtop genomic sequencer designed to produce fast and accurate results. The company currently developing the G4X Spatial Sequencer, which will leverage its proprietary sequencing technology, applying it as an in situ readout for transcriptomics, proteomics, and fluorescent H&E in tissue, with spatial context and on the same platform as the G4.. Singular Genomics was formed in 2016 and is based in San Diego, California. |
Buy | - |
